Hide metadata

dc.date.accessioned2016-08-17T08:30:14Z
dc.date.available2016-08-17T08:30:14Z
dc.date.created2016-01-28T15:36:26Z
dc.date.issued2015
dc.identifier.citationYu, Dandan Zhong, Yali Li, Xiaoran Li, Yaqing Li, Xiaoli Cao, Jing Fan, Huijie Yuan, Yuan Ji, Zhenyu Qiao, Baoping Wen, Jianguo Zhang, Mingzhi Kvalheim, Gunnar Nesland, Jahn M Suo, Zhenhe . ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro. OncoTarget. 2015, 6(40), 42687-42703
dc.identifier.urihttp://hdl.handle.net/10852/51259
dc.description.abstractCancer stem cells (CSCs) are associated with cancer recurrence and metastasis. Prostate cancer cells often metastasize to the bone with a complex microenvironment of cytokines favoring cell survival. In this study, the cell stemness influence of a group of interleukins including IL-3, 6, 10, 11 and 24 on human prostate cancer cell lines LNCaP and PC-3 was explored in vitro. Sulforhodamine B(SRB) and 5-ethynyl-2′-deoxyuridine (EdU) assays were applied to examine the effect on cell proliferation, and wound healing and transwell assays were used for migration and invasion studies, in addition to colony formation, Western blotting and flowcytometry for the expression of stemness factors and chemotherapy sensitivity. We observed that ILs-3, 6 and 11 stimulated while ILs-10 and 24 inhibited the growth, invasion and migration of both cell lines. Interestingly, ILs-3, 6 and 11 significantly promoted colony formation and increased the expression of SOX2, CD44 and ABCG2 in both prostate cancer cell lines. However, ILs-10 and 24 showed the opposite effect on the expression of these factors. In line with the above findings, treatment with either IL-3 or IL-6 or IL-11 decreased the chemosensitivity to docetaxel while treatment with either IL-10 or IL-24 increased the sensitivity of docetaxel chemotherapy. In conclusion, our results suggest that ILs-3, 6 and 11 function as tumor promoters while ILs-10 and 24 function as tumor suppressors in the prostate cancer cell lines PC-3 and LNCaP in vitro, and such differences may attribute to their different effect on the stemness of PCa cells.en_US
dc.languageEN
dc.language.isoenen_US
dc.publisherImpact Journals LLC
dc.rightsAttribution 3.0 Unported
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/
dc.titleILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitroen_US
dc.typeJournal articleen_US
dc.creator.authorYu, Dandan
dc.creator.authorZhong, Yali
dc.creator.authorLi, Xiaoran
dc.creator.authorLi, Yaqing
dc.creator.authorLi, Xiaoli
dc.creator.authorCao, Jing
dc.creator.authorFan, Huijie
dc.creator.authorYuan, Yuan
dc.creator.authorJi, Zhenyu
dc.creator.authorQiao, Baoping
dc.creator.authorWen, Jianguo
dc.creator.authorZhang, Mingzhi
dc.creator.authorKvalheim, Gunnar
dc.creator.authorNesland, Jahn M
dc.creator.authorSuo, Zhenhe
cristin.unitcode185,53,18,13
cristin.unitnameAvdeling for patologi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1325454
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=OncoTarget&rft.volume=6&rft.spage=42687&rft.date=2015
dc.identifier.jtitleOncoTarget
dc.identifier.volume6
dc.identifier.issue40
dc.identifier.startpage42687
dc.identifier.endpage42703
dc.identifier.doihttp://dx.doi.org/10.18632/oncotarget.5883
dc.identifier.urnURN:NBN:no-54708
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn1949-2553
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/51259/1/5883-102175-1-PB.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution 3.0 Unported
This item's license is: Attribution 3.0 Unported